Brain Metastases Program

In December, 2012, the USFDA granted Diffusion Pharmaceuticals an Orphan Designation for the use of TSC in brain metastases. Planning for a clinical trial testing TSC in this indication is on-going, with enrollment expected to begin subsequent to initiation of the clinical trials in GBM and acute stroke.


Because of the safety history of TSC to date, Diffusion should be able to move directly into Phase 2 trials for this indication.